Syndax Pharmaceuticals (NASDAQ:SNDX) versus Biofrontera (NASDAQ:BFRI) Head to Head Contrast

Syndax Pharmaceuticals (NASDAQ:SNDXGet Free Report) and Biofrontera (NASDAQ:BFRIGet Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, risk, valuation, profitability, earnings, institutional ownership and dividends.

Volatility and Risk

Syndax Pharmaceuticals has a beta of 1.03, suggesting that its stock price is 3% more volatile than the S&P 500. Comparatively, Biofrontera has a beta of 0.83, suggesting that its stock price is 17% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Syndax Pharmaceuticals and Biofrontera, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Syndax Pharmaceuticals 0 1 9 0 2.90
Biofrontera 0 0 1 0 3.00

Syndax Pharmaceuticals currently has a consensus price target of $34.42, suggesting a potential upside of 65.46%. Biofrontera has a consensus price target of $18.00, suggesting a potential upside of 965.09%. Given Biofrontera’s stronger consensus rating and higher probable upside, analysts plainly believe Biofrontera is more favorable than Syndax Pharmaceuticals.

Earnings and Valuation

This table compares Syndax Pharmaceuticals and Biofrontera’s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Syndax Pharmaceuticals $139.71 million 12.65 -$209.36 million ($2.96) -7.03
Biofrontera $34.07 million 0.25 -$20.13 million ($15.82) -0.11

Biofrontera has lower revenue, but higher earnings than Syndax Pharmaceuticals. Syndax Pharmaceuticals is trading at a lower price-to-earnings ratio than Biofrontera, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

10.1% of Biofrontera shares are owned by institutional investors. 4.1% of Syndax Pharmaceuticals shares are owned by company insiders. Comparatively, 0.7% of Biofrontera shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.


This table compares Syndax Pharmaceuticals and Biofrontera’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Syndax Pharmaceuticals N/A -47.88% -44.00%
Biofrontera -59.09% -344.98% -72.85%


Syndax Pharmaceuticals beats Biofrontera on 9 of the 14 factors compared between the two stocks.

About Syndax Pharmaceuticals

(Get Free Report)

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.

About Biofrontera

(Get Free Report)

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.

Receive News & Ratings for Syndax Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syndax Pharmaceuticals and related companies with's FREE daily email newsletter.